ATE327747T1 - Therapeutische kombination des ascorbats mit lysin und arginin für verhinderung und behandlung des krebses - Google Patents

Therapeutische kombination des ascorbats mit lysin und arginin für verhinderung und behandlung des krebses

Info

Publication number
ATE327747T1
ATE327747T1 AT00121950T AT00121950T ATE327747T1 AT E327747 T1 ATE327747 T1 AT E327747T1 AT 00121950 T AT00121950 T AT 00121950T AT 00121950 T AT00121950 T AT 00121950T AT E327747 T1 ATE327747 T1 AT E327747T1
Authority
AT
Austria
Prior art keywords
lysine
cancer
treatment
ascorbate
arginine
Prior art date
Application number
AT00121950T
Other languages
English (en)
Inventor
Matthias Dr Med Rath
Original Assignee
Matthias Dr Med Rath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matthias Dr Med Rath filed Critical Matthias Dr Med Rath
Application granted granted Critical
Publication of ATE327747T1 publication Critical patent/ATE327747T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00121950T 2000-10-09 2000-10-09 Therapeutische kombination des ascorbats mit lysin und arginin für verhinderung und behandlung des krebses ATE327747T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00121950A EP1195159B1 (de) 2000-10-09 2000-10-09 Therapeutische Kombination des Ascorbats mit Lysin und Arginin für Verhinderung und Behandlung des Krebses

Publications (1)

Publication Number Publication Date
ATE327747T1 true ATE327747T1 (de) 2006-06-15

Family

ID=8170040

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00121950T ATE327747T1 (de) 2000-10-09 2000-10-09 Therapeutische kombination des ascorbats mit lysin und arginin für verhinderung und behandlung des krebses

Country Status (6)

Country Link
EP (1) EP1195159B1 (de)
AT (1) ATE327747T1 (de)
DE (1) DE60028376T2 (de)
DK (1) DK1195159T3 (de)
ES (1) ES2261136T3 (de)
PT (1) PT1195159E (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77660C2 (en) * 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
WO2003017942A2 (en) * 2001-08-24 2003-03-06 Rath Matthias M D Ascorbic acid derivatives with amino acids
RU2301666C2 (ru) * 2002-01-11 2007-06-27 Маттиас Рат Обладающий питательными свойствами фармацевтический состав на основе полифенолов и его использование при лечении рака
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
GB0212405D0 (en) * 2002-05-29 2002-07-10 Insignion Holdings Ltd Composition and its therapeutic use
CA2524381A1 (en) * 2003-05-30 2004-12-16 Matthias Rath Nutritional composition and method of inhibiting smooth muscle cell contraction thereof
US20050053673A1 (en) * 2003-09-05 2005-03-10 Shrirang Netke Composition and method for facilitating bone healing
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
EP1874354A1 (de) * 2005-04-11 2008-01-09 Rath, Matthias Nährstoffzusammensetzung mit polyphenolen von grünem tee zur behandlung von osteosarkom
FR2884692B1 (fr) * 2005-04-21 2009-08-14 Formquest Ltd Complement alimentaire comprenant une association d'agents antioxydants et de carnitine, obtenue par synthese endogene ou exogene, comme aide a la fertilite chez l'homme et chez la femme
ATE554663T1 (de) * 2005-07-29 2012-05-15 Tima Foundation Zusammensetzung zur steuerung des alkohol metabolismus und zur reduktion des risikos von alkoholbedingten krankheiten
WO2007016951A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risc of alcohol induced pancreatic cancer
WO2007016954A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing drug or alcohol induced breast cancer risk
US20070054890A1 (en) 2005-07-29 2007-03-08 Alkon Daniel L Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
WO2007016949A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risc of alcohol induced neuropathy
WO2007016950A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risk of alcohol induced neurodegenerative disease
WO2007016952A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risk of alcohol induced esophagenal and oropharyngolaryngeal cancer
WO2007016953A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing alcohol induced liver cancer risk
CN101848726A (zh) 2007-02-09 2010-09-29 布朗歇特洛克菲勒神经科学研究所 苔藓抑素、苔藓抑素类似物和其它相关物质对头部创伤引起的记忆缺陷和脑损伤的疗效
WO2010011927A1 (en) 2008-07-25 2010-01-28 Noventis, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
CN108420827A (zh) * 2010-07-22 2018-08-21 雷文制药有限公司 包含磁偶极子稳定化溶液的组合物及其用途
AT510810B1 (de) * 2010-12-09 2017-09-15 Gonadosan Gmbh Kombinationspräparat zur verbesserung der weiblichen fertilität
WO2022124386A1 (en) * 2020-12-07 2022-06-16 L' Oreal Composition comprising ascorbic acid and cyclic amino acid
CN113082051B (zh) * 2021-03-29 2022-10-25 北京诺康达医药科技股份有限公司 一种复方维生素和微量元素口服溶液及其制备方法
US11679096B1 (en) * 2022-05-04 2023-06-20 Matthias W. Rath Composition and method of treatment of elevated ApoE gene expression related health issues

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535049A (en) * 1978-09-04 1980-03-11 Otsuka Pharmaceut Factory Inc Amino acid transfusion for cancerous patient
DE3440090A1 (de) * 1984-11-02 1986-05-07 Novo-Med AG, Appenzell Aminosaeureloesungen enthaltendes arzneimittel zur therapie von krebserkrankungen und verfahren zu seiner herstellung
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
US5198465A (en) * 1991-06-19 1993-03-30 Dioguardi Francesco S Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
GB2268871A (en) * 1992-07-04 1994-01-26 Bio Nutritional Health Service Composition for use as a food or food supplement
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5626883A (en) * 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
EP0891771A1 (de) * 1997-07-08 1999-01-20 Health Now, Inc. Lysin und Ascorbat oder ihre Derivate zur Behandlung von kardiovaskulären Erkrankungen

Also Published As

Publication number Publication date
ES2261136T3 (es) 2006-11-16
EP1195159B1 (de) 2006-05-31
PT1195159E (pt) 2006-08-31
DK1195159T3 (da) 2006-10-02
EP1195159A1 (de) 2002-04-10
DE60028376D1 (de) 2006-07-06
DE60028376T2 (de) 2007-06-06

Similar Documents

Publication Publication Date Title
DE60028376D1 (de) Therapeutische Kombination des Ascorbats mit Lysin und Arginin für Verhinderung und Behandlung des Krebses
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
DE60043318D1 (de) Synergistische kombination von pumafentrine und salmeterol
ATE136030T1 (de) Azaheterocyclylmethyl-chromane als wirkstoffe zur behandlung von erkrankungen des zentralnervensystems
DE59100067D1 (de) Orale arzneimittelformen von pimobendan.
CY1111999T1 (el) Λακτοφερρινη στην αγωγη κακοηθων νεοπλασματων και αλλων υπερπλαστικων νοσων
AR027355A1 (es) Acidos tiazolidincarboxilicos
DE69007319D1 (de) Zusammensetzungen zur Behandlung von Neoplasia mit Gehalt an neoplasmushemmendem Mittel und Nebenwirkungen reduzierendem Schutzmittel.
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
EP1283038A4 (de) Zusammensetzungen zur normalisierung des zirkadianen rythmus
LT2004074A (en) Matricines metalproteinazes inhibuojanti kompozicija neoplazinems ligoms gydyti
DK1001775T3 (da) Medikament indeholdende yohimbin og arginin beregnet til behandling af erektil dysfunktion
CY1107312T1 (el) Θειικη 3,5,3’-τριιωδοθυρονινη σαν θυρεοειδο-μιμητικος παραγοντας και φαρμακευτικα σκευασματα της
NO924453D0 (no) Fremgangsmaate for fremstilling av et pasteurisert trombinkonsentrat
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
ES2175006T3 (es) N-(pirimidinil)-benzosulfonamidas como medicamentos.
DE60019937D1 (de) Kombination therapie mit pentafluorobenzenesulfonamid und platin-derivate
DE59206036D1 (de) Piperidylmethyl substituierte Chromanderivate als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems
WO1999011256A8 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
DE68901948D1 (de) Produkt, zusammensetzungen und behandlungen zur verhinderung des zusammenbackens von salzen, einnaehrstoffduengern und mehrnaehrstoffduengern.
DE69528068D1 (de) Conagenine zur prävention und behandlung von diarrhöe
ATE313547T1 (de) 2-methyl-3-butenyl-1-pyrophosphorsäuresalze und mittel zur behandlung von lymphozyten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1195159

Country of ref document: EP